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Anders Woetmann1,2 and Niels Odum1,2
IL-17 is a proinflammatory cytokine that is crucial for the host’s protection against a range of extracellular
pathogens. However, inappropriately regulated expression of IL-17 is associated with the development of
inflammatory diseases and cancer. In cutaneous T-cell lymphoma (CTCL), malignant T cells gradually accumulate
in skin lesions characterized by massive chronic inflammation, suggesting that IL-17 could be involved in the
pathogenesis. In this study we show that IL-17 protein is present in 10 of 13 examined skin lesions but not in sera
from 28 CTCL patients. Importantly, IL-17 expression is primarily observed in atypical lymphocytes with
characteristic neoplastic cell morphology. In accordance, malignant T-cell lines from CTCL patients produce
IL-17 and the synthesis is selectively increased by IL-2 receptor b chain cytokines. Small-molecule inhibitors or
small interfering RNA against Jak3 and signal transducer and activator of transcription 3 (Stat3) reduce the
production of IL-17, showing that the Jak3/Stat3 pathway promotes the expression of the cytokine. In summary,
our findings indicate that the malignant T cells in CTCL lesions express IL-17 and that this expression is
promoted by the Jak3/Stat3 pathway.
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INTRODUCTION
IL-17 is a proinflammatory cytokine that is mainly produced
by Th17 cells, but also expressed by other cell types such as
gd T cells, CD8þ T cells, natural killer T cells, natural killer
cells, and neutrophils. It is crucial for the host’s defense
against a range of extracellular pathogens; however, inap-
propriately regulated expression of IL-17 is associated with
the development of a variety of inflammatory and auto-
immune diseases (Weaver et al., 2007; Korn et al., 2009;
Miossec et al., 2009). A link between chronic inflammation
and cancer has long been recognized with several recent
studies defining the role of IL-17 in carcinogenesis. It has
been shown that IL-17 can act directly on some tumor cells
and elicit production of cytokines as well as foster their
proliferation and survival. IL-17 can also promote
tumor growth indirectly by stimulating the secretion of
angiogenic factors such as vascular endothelial growth factor
and IL-8 from tumor and/or stromal cells, resulting in
increased tumor vascularization. Moreover, IL-17 can induce
secretion of chemokines, matrix metalloproteinases, and
proinflammatory cytokines from stromal cells, leading to
recruitment and activation of inflammatory cells, thereby
promoting chronic inflammation. Finally, IL-17 has also been
shown to inhibit tumorigenesis, in part by enhancing
cytotoxic antitumor responses (Murugaiyan and Saha, 2009;
Ji and Zhang, 2010; Zou and Restifo, 2010). Thus, it seems
that the role of IL-17 in carcinogenesis is complex,
exerting both pro- and anti-tumor effects, depending on the
specific context.
Cutaneous T-cell lymphoma (CTCL) defines a heteroge-
neous group of neoplastic disorders characterized by chronic
inflammation and primary accumulation of malignant T cells
in the skin. The predominant clinical form of CTCL is mycosis
fungoides (MF) (Willemze et al., 2005). In the initial stages of
classical MF, patients presents with flat erythematous skin
patches that resemble lesions from nonmalignant inflamma-
tory skin disorders like chronic eczema, allergic contact
dermatitis, large-plaque parapsoriasis, and psoriasis. These
lesions contain dermal infiltrates composed of a variety of
inflammatory cells including T cells with normal morphology
as well as atypical T cells with a distinctive neoplastic
morphology. Typically, the malignant T cells infiltrate the
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epidermis and form Pautrier microabscesses, which are
collections of T cells adherent to dendritic processes of
Langerhans cells. During disease progression, the composi-
tion of the dermal infiltrates changes and the malignant T
cells eventually predominate, leading to the development of
overt tumors (Girardi et al., 2004; Kim et al., 2005; Hwang
et al., 2008). The progression of MF is sometimes associated
with a large cell transformation of the malignant T cells. The
prognosis for transformed MF is very poor with a mean
survival of 22 months (Vergier et al., 2000). Se´zary syndrome
(SS) is a particular aggressive variant of CTCL characterized
by generalized erythroderma, lymphadenopathy, and the
presence of high numbers of T cells with atypical cerebriform
nuclei (Se´zary cells) in the peripheral blood (Vonderheid
et al., 2002).
The etiology and pathogenesis of CTCL remain poorly
understood. However, cytokines that signal through receptors
containing the common cytokine receptor g chain (gc) have
been shown to be vital for the ex vivo survival and
proliferation of the malignant T cells. Because some of these
gc cytokines are present in CTCL patients, it has been
suggested that they have an important role in the pathogen-
esis (Dobbeling et al., 1998; Leroy et al., 2001; Yamanaka
et al., 2006b; Marzec et al., 2008). Accordingly, the Jak3/
signal transducer and activator of transcription 3 (Stat3)
pathway is active in the malignant T cells promoting their
survival (Zhang et al., 1996; Eriksen et al., 2001; Sommer
et al., 2004). In a fraction of CTCL patients, the malignant T
cells harbor activating mutations in Jak3 that can confer
cytokine-independent activation of the Jak3/Stat3 pathway
(Cornejo et al., 2009).
In addition to numerous inflammatory cells, a plethora of
cytokines (e.g., tumor necrosis factor-a, IL-1, IL-4, IL-5, IL-15,
IL-18, and IL-23) (Hansen et al., 1991; Vowels et al., 1994;
Daliani et al., 1998; Dobbeling et al., 1998; Leroy et al.,
2001; Doherty et al., 2006; Yamanaka et al., 2006a),
chemokines (e.g., CCL17 (chemokine (C-C motif) ligand
17), CCL20, and CCL22) (Ferenczi et al., 2002; Schmuth
et al., 2002) matrix metalloproteinases (e.g., MMP2 and
MMP9) (Vacca et al., 1997), and angiogenic factors (e.g.,
vascular endothelial growth factor and IL-8) (Hansen et al.,
1991; Krejsgaard et al., 2006) are frequently present in CTCL
skin lesions. The malignant progression in a chronic
inflammatory environment suggests that IL-17 could be
involved in the pathogenesis of CTCL. Supporting this
hypothesis, a previous study found IL-17 mRNA in 5 out of
10 biopsies from CTCL patients (Ciree et al., 2004). In this
study we show that IL-17 protein is present in 10 of 13
examined skin lesions but not in sera from 28 CTCL patients.
Interestingly, IL-17 immunoreactivity is primarily localized to
lymphocytes with characteristic malignant cell morphology,
strongly suggesting that IL-17 is expressed by the tumor cells
in situ. Furthermore, malignant CTCL T-cell lines produce
IL-17 and the synthesis is selectively increased by IL-2 and
IL-15, which are the two IL-2 receptor b chain (IL-2Rb)-
specific members of the gc cytokine family. Small-molecule
inhibitors or small interfering RNAs (siRNAs) against Jak3 and
Stat3 inhibit the IL-17 production, indicating that activation
of the Jak3/Stat3 pathway promotes the malignant expression
of IL-17.
RESULTS
IL-17 is present in skin lesions but not sera from CTCL patients
To investigate if IL-17 protein is present in CTCL lesions, we
performed immunohistochemical stainings of skin biopsy
specimens from 13 patients diagnosed with different stages of
CTCL and three patients with benign dermatoses using an
anti-IL-17 antibody. As shown in Table 1, skin lesions from
10 of the 13 CTCL patients stained positive for IL-17, whereas
affected skin from patients with benign dermatoses stained
negative (Po0.05, Fisher’s exact test). A positive IL-17
staining was observed in 1 of 1 MF plaque lesions, 3 of 4
MF tumor lesions, 3 of 4 transformed MF lesions, and 3 of 4
SS lesions, suggesting that IL-17 expression occurs in all
stages of CTCL (Table 1).
Figure 1 shows representative pictures of the immunohis-
tochemical stainings of an MF plaque lesion, an MF tumor
lesion, SS lesions, and a benign dermatosis. Interestingly,
IL-17 positivity was primarily localized to atypical lympho-
cytes in the dermis and epidermis with characteristic
neoplastic morphology, indicating that the malignant T cells
express IL-17 in situ (Figure 1a–c). Accordingly, most of the
lymphocytes in Pautrier microabscesses stained for IL-17, and
overall the majority of the epidermotropic lymphocytes were
Table 1. IL-17 expression in CTCL skin lesions
Patient Diagnosis IL-17
1 MF plaque +
2 MF tumor 
3 MF tumor +
4 MF tumor +
5 MF tumor +
6 MF tumor,
transformed

7 MF tumor,
transformed
+
8 MF tumor,
transformed
+
9 MF tumor,
transformed
+
10 SS +
11 SS +
12 SS 
13 SS +
14 Benign dermatosis 
15 Benign dermatosis 
16 Benign dermatosis 
Abbreviations: CTCL, cutaneous T-cell lymphoma; MF, mycosis
fungoides; SS, Se´zary syndrome.
+ And  indicate that the lesions stained positive or negative for IL-17,
respectively.
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IL-17 positive (Figure 1a and b). It is noteworthy that in all
samples (including benign dermatoses) the antibody exhib-
ited some degree of unspecific binding that gave rise to a
weak staining that was preferentially localized to the
epidermal keratinocytes—a pattern distinctly different from
the positive staining in areas of atypical lymphocytes (Figure
1a). One patient with tumor stage MF, one with transformed
MF, and one SS patient were IL-17 negative (Table 1 and
Figure 1c), indicating that IL-17 expression is a marker of
disease heterogeneity as suggested in a previous study on
IL-17 mRNA expression in CTCL skin lesions (Ciree et al., 2004).
Having found IL-17 expression in CTCL skin lesions, we
asked if IL-17 was also present in the peripheral blood of the
patients. Consequently, we examined the concentration of
IL-17 in serum samples from 8 healthy donors and 28 patients
with different clinical stages of CTCL (Ib, IIa, IIb, III, IVa, and
IVb) using an IL-17-specific ELISA with a sensitivity of
10 pgml–1. As expected, IL-17 was not detected in the sera
from the healthy individuals but could be identified in all 8
serum samples spiked with 200 pgml–1 IL-17 with a mean
recovery of 100.3% (Figure 2a). However, IL-17 was not
detected in the sera of any of the 28 patients, indicating that
IL-17 is not present in the peripheral blood of CTCL patients
but restricted to the skin lesions (data not shown). Supporting
this finding, IL-17 mRNA was not expressed in peripheral
blood mononuclear cells isolated from two SS patients with
high numbers of malignant T cells in the peripheral blood
(Figure 2b).
IL-17 is produced by malignant CTCL T-cell lines
To provide additional evidence that malignant CTCL
cells produce IL-17, we analyzed if two malignant (SeAx
MF plaque, positive
MF plaque MF tumor SS
Benign dermatosis SS, positive SS, negative
Figure 1. IL-17 is expressed by neoplastic lymphocytes in cutaneous T-cell lymphoma (CTCL) skin lesions. Representative pictures of (a) an IL-17-positive
plaque lesion and a benign dermatosis, (b) a mycosis fungoides (MF) plaque, an MF tumor, and a Se´zary syndrome (SS) skin lesion, all positive for IL-17,
and (c) an IL-17-positive and an IL-17-negative SS skin lesion. Scale bar¼ 100mm.
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and SeZ-4) T-cell lines and a nonmalignant (MySi) T-cell line
established from patients with CTCL expressed IL-17. In
accordance with our previous findings, the two malignant
T-cell lines but not the non-malignant T-cell line expressed
IL-17 mRNA (Figure 2b and data not shown) and secreted
IL-17 protein (Figure 3). Interestingly, the secretion of IL-17
was strongly increased when the malignant T cells
were stimulated with the IL-2Rb cytokines IL-2 and IL-15
(Figure 3). The increased levels of IL-17 were not simply a
result of increased numbers of the malignant T cells due to
the proliferative effect of the IL-2Rb cytokines, as increased
levels of IL-17 were observed before an increase in the total
protein levels and as the increase of IL-17 was evident after
normalization to the total protein levels (Supplementary
Figure S1 online). In contrast to IL-2 and IL-15, stimulation
with other gc cytokine family members (IL-4, IL-7, IL-9, and
IL-21) or IL-23 did not increase the malignant secretion of IL-
17 (Supplementary Figure S2 online). It is noteworthy that the
malignant CTCL T-cell line HUT-78 did not secrete IL-17
even after cytokine stimulation, which is in accordance with
our finding that malignant expression of IL-17 is not observed
in all CTCL patients (data not shown).
The expression of IL-17 is promoted by the Jak3/Stat3 pathway
Next, we sought to identify the molecular mechanisms
driving the expression of IL-17 by the malignant T cells.
The Jak3/Stat3 signaling pathway is normally activated in the
malignant T cells in CTCL lesions and is believed to have a
central pathogenic role (Zhang et al., 1996; Sommer et al.,
2004; Krejsgaard et al., 2009). Because Stat3 has been
identified as an important regulator of IL-17 expression in
normal T cells (Korn et al., 2009) and IL-2Rb cytokines
increase the Jak3-dependent activation of Stat3 in CTCL cells
(Kasprzycka et al., 2008; Marzec et al., 2008), we explored if
the Jak3/Stat3 pathway was involved in the IL-17 production
by the CTCL cells. As shown in Figure 4, treatment of the
SeAx cells with a small-molecule Jak3 kinase inhibitor
significantly reduced the expression of IL-17 mRNA and
protein, whereas inhibitors against several non-Jak kinases
had no significant effect (Figure 4a and b). Similarly, the
highly specific Jak3 inhibitor CP-690,550 mediated a dose-
dependent inhibition of Stat3 activity that correlated with
reduced levels of IL-17 induction (Supplementary Figure S3
online). The downregulation of Jak3 expression by Jak3-
specific siRNA also inhibited the IL-17 production, whereas
Stat5 siRNA significantly increased the expression of IL-17
from SeAx cells treated with IL-2 (Figure 4c). In contrast, both
a small-molecule Stat3 inhibitor and Stat3 siRNA reduced the
IL-17 production induced by IL-2 (Figure 5a and b).
Immunohistochemical stainings against active Stat3 (pYStat3)
on 12 of the CTCL lesions previously analyzed for IL-17
showed that 9 of 11 pYStat3-positive lesions were also IL-17
positive and that one lesion that was pYStat3 negative was
also negative for IL-17 (Supplementary Figure S4 online).
DISCUSSION
IL-17 is a proinflammatory cytokine that has been associated
with the development of inflammatory diseases and cancer
(Weaver et al., 2007; Korn et al., 2009; Miossec et al., 2009).
In this study, we show that IL-17 protein is expressed in skin
lesions from 10 of 13 CTCL patients. This finding is in keeping
with a previously reported identification of IL-17 mRNA in 5
of 10 CTCL skin biopsies. However, the exact cellular source
of the IL-17 mRNA was not identified by the reverse
transcriptase-PCR-based tissue analysis (Ciree et al., 2004).
Here, we found IL-17 protein immunoreactivity primarily
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Figure 2. IL-17 is not expressed in the peripheral blood of cutaneous T-cell
lymphoma (CTCL) patients. (a) Spike-recovery test of the ELISA used for
detection of IL-17 in human serum. A total of 200 pgml–1 IL-17 or the
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Figure 3. Malignant but not nonmalignant cutaneous T-cell lymphoma
(CTCL) T-cell lines express IL-17. Malignant (SeAx, SeZ-4) and nonmalignant
(MySi) T cells were cultured for 24 hours with IL-2 (500Uml–1), IL-15
(20 ngml–1), or vehicle () and the concentration of IL-17 in the supernatant
determined by ELISA. Each bar is the meanþ SEM of three replicates.
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localized to atypical lymphocytes with characteristic neo-
plastic cell morphology in CTCL skin lesions. Moreover,
malignant T-cell lines established from CTCL patients
secreted IL-17, indicating that malignant CTCL cells express
IL-17 in situ. Supporting this notion, Ciree et al. (2004)
showed that malignant T cells purified from the peripheral
blood of CTCL patients produced IL-17 in vitro after
activation with phorbol 12-myristate 13-acetate and iono-
mycin. As we did not detect IL-17 in serum or peripheral
blood mononuclear cells from CTCL patients, it seems that
the malignant T cells in the peripheral blood are not
appropriately activated to produce IL-17. This possibility
would imply the presence of factors in the skin lesions that
locally stimulate the tumor cells to produce IL-17. We found
that the IL-2Rb-specific cytokines IL-2 and IL-15 potently
increased IL-17 expression by the malignant T cells. It has
previously been shown that IL-15 is produced by keratino-
cytes in CTCL lesions, identifying IL-15 as one likely factor
that could stimulate the expression of IL-17 by the malignant
CTCL cells (Dobbeling et al., 1998; Leroy et al., 2001). In line
with this hypothesis, other studies demonstrated that IL-15
triggers overproduction of IL-17 in rheumatoid arthritis
(Ziolkowska et al., 2000; Yoshihara et al., 2007). Our results
show that the IL-2Rb cytokine-induced expression of IL-17 is
mediated through a Jak3/Stat3-dependent mechanism and
repressed by Stat5. Because other members of the gc cytokine
family can increase the activity of Jak3 and Stat3 in the
malignant T cells (Marzec et al., 2008), the present findings
suggest that the ability of Stat3 to induce expression of IL-17
is subject to regulation by other factors. This conclusion is in
agreement with the observation that 2 of the 11 CTCL lesions
were pYStat3 positive but not positive for IL-17. However, 9
of 11 CTCL lesions stained positive for both pYStat3 and IL-17
and one lesion that was negative for pYStat3 was also IL-17
negative, which is in accordance with a role of Stat3 in
promoting the malignant expression of IL-17.
Ciree et al. (2004) found that malignant CTCL cell lines
expressed IL-17 receptor A but that exogenous IL-17 did not
influence their proliferation or cytokine production, and we
obtained similar results in a series of studies of malignant
growth in vitro (data not shown). Similarly, normal T cells
exhibit no or very subtle responses to IL-17, although they
express IL-17 receptor A (Gaffen, 2009). Together, these
observations suggest that IL-17 does not function as an
autocrine factor for the malignant T cells. Receptors for IL-17
are also expressed by fibroblasts, keratinocytes, and epithelial
cells. In contrast to T cells, these cell types typically produce
a variety of proinflammatory cytokines, chemokines, matrix
metalloproteinases, and angiogenic proteins when stimulated
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Figure 4. The expression of IL-17 is promoted by Jak3. (a) SeAx cells were
incubated for 30minutes with 40 mgml–1 Jak3 inhibitor (Jak3I) or vehicle ().
Then, 500Uml–1 IL-2 or phosphate-buffered saline (PBS; ) was added and
the cells incubated for 4 hours further before the relative levels of IL-17 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were
determined by quantitative PCR (qPCR). In each sample, the level of IL-17
mRNA was normalized to that of GAPDH mRNA and depicted as fold change
when compared with cells cultured without IL-2 and inhibitor. (b) SeAx cells
were incubated for 30minutes with inhibitors against Jak3 (Jak3I, 40mgml–1),
JNK (Sp600125, 5 mM), Lck (LckI, 5 mM), EGFR (Ag1478, 200 ngml–1), or
vehicle () before addition of 500Uml–1 IL-2 or PBS (). The cells were then
incubated for 24 hours and the concentrations of IL-17 in the supernatants
determined by ELISA. (c) SeAx cells were transiently transfected with
nontargeting (NT) small interfering RNA (siRNA) or siRNA against Jak3 or
signal transducer and activator of transcription 5 (Stat5). At 24 hours after
transfection, the cells were washed and cultured with 500Uml–1 IL-2 or PBS
() for another 24 hours. Finally, the concentrations of IL-17 in the
supernatants were determined by ELISA and the cellular expression of Jak3,
Stat5, and extracellular signal-regulated kinases 1 and 2 (Erk1/2) analyzed by
western blotting. Bars represent meanþ SEM, n¼ 3–4. *Po0.05.
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with IL-17 (Kanda et al., 2005; Koga et al., 2008; Nograles
et al., 2008; Gaffen, 2009; Harper et al., 2009; Miossec et al.,
2009). Interestingly, CTCL lesions exhibit increased angio-
genesis, and several angiogenic and inflammatory proteins
that are known to be induced by IL-17 (e.g., tumor necrosis
factor-a, CCL20, MMP-9, COX-2, vascular endothelial
growth factor, and IL-8) have been reported to be present in
CTCL lesions (Hansen et al., 1991; Vacca et al., 1997;
Daliani et al., 1998; Schmuth et al., 2002; Mazur et al., 2004;
Krejsgaard et al., 2006; Kopp et al., 2010). Therefore, it seems
plausible that IL-17 indirectly influences CTCL tumorigenesis
by modulating angiogenesis and inflammation; however,
whether IL-17 has an overall pro- or anti-tumorigenic role
remains to be established. We speculate that IL-2Rb
cytokines, in cooperation with other lesional factors, stimu-
late the malignant T cells to express IL-17 and that IL-17, in
turn, stimulates the stromal cells to secrete angiogenic
factors, proinflammatory cytokines, and chemokines that
contribute to tumorigenesis by promoting angiogenesis and
chronic inflammation. In this context, it is interesting that
neutralizing antibodies against IL-17 are now in clinical trails
for treatment of inflammatory and autoimmune diseases
(Genovese et al., 2010). Furthermore, our findings suggest
that drugs targeting the Jak3/Stat3 pathway could inhibit the
expression of IL-17. Importantly, several potent and relatively
selective inhibitors of Jak3 have been developed. The most
clinically advanced compound is the orally active Jak3
inhibitor CP-690,550 that has shown promising results in
phase II clinical trials for the therapy of rheumatoid arthritis,
psoriasis, and the prevention of renal transplant rejection
with relatively few side effects at effective doses (Pesu et al.,
2008; West, 2009; Wilson, 2010). The compound is currently
in a phase III clinical trial investigating the efficacy and safety
in patients with active rheumatoid arthritis on background
methotrexate. Therefore, it was of particular interest that CP-
690,550 potently abrogated the cytokine-induced IL-17
production from the malignant T-cell lines. As the expression
of IL-17 was promoted by Stat3 and repressed by Stat5,
selective inhibition of Stat3 activity could also provide a
rational strategy for suppression of IL-17 production. How-
ever, although several Stat3 inhibitors have been developed,
so far no clinical trails of direct Stat3 inhibitors have been
published (Yue and Turkson, 2009).
In conclusion, our findings indicate that the malignant T
cells in CTCL lesions express IL-17 and that this expression is
promoted by the Jak3/Stat3 pathway.
MATERIALS AND METHODS
Reagents
Antibodies against Jak3 and Erk1/2 (extracellular signal-regulated
kinases 1 and 2) were from Santa Cruz Biotechnology (Santa Cruz,
CA). The antibody against Stat3 was from Cell Signaling Technology
(Beverly, MA) and the Stat5 antibody from Becton Dickinson
(Franklin Lakes, NJ). The Lck inhibitor (LckI) and Jak3 inhibitor II
(Jak3I; WHI-P154) were from Calbiochem (San Diego, CA), whereas
Sp600125, Sta-21, and Tyrphostin Ag1478 were from Enzo Life
Sciences (Plymouth Meeting, PA). Finally, DMSO was from Sigma-
Aldrich (St Louis, MO), recombinant human IL-2 (Proleukin) from
Chiron (Emeryville, CA), and recombinant human IL-15 from Leinco
Technologies (St Louis, MO).
Patients and immunohistochemistry
Paraffin-embedded skin biopsies from patients diagnosed with CTCL
during the period 1979–2004 were drawn from the archives of the
Department of Pathology at Rigshospitalet. For immunohistochem-
ical analysis of IL-17, the biopsies were pre-treated in a microwave
oven in TEG buffer (pH 9) and then incubated with an anti-IL-17
antibody (H132; Santa Cruz Biotechnology) diluted 1:100 for
60minutes. Staining was performed using the DAKO EnVi-
sionHRP/Rabbit kit (DAKO, Hamburg, Germany) as previously
described (Gjerdrum et al., 2007). Controls consisted of cell lines
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Figure 5. The expression of IL-17 is promoted by signal transducer and
activator of transcription 3 (Stat3). (a) SeAx cells were initially incubated for
30minutes with inhibitors against Jak3 (Jak3I, 40 mgml–1), Stat3 (Sta-21,
40mM), EGFR (Ag1478, 200 ngml–1), or vehicle (). Then, 500Uml–1 IL-2 or
phosphate-buffered saline (PBS; ) was added and the cells incubated for
24 hours before the IL-17 concentrations in the supernatants were determined
by ELISA. Bars represent meanþ SEM, n¼ 3. *Po0.05. (b) SeAx cells were
transiently transfected with nontargeting (NT) small interfering RNA (siRNA)
or siRNA against Stat3. At 24 hours after transfection, the cells were washed
and cultured with 500Uml–1 IL-2 or PBS () for another 24 hours. Finally, the
concentrations of IL-17 in the supernatants were determined by ELISA and the
cellular expression of Stat3 and extracellular signal-regulated kinases 1 and 2
(Erk1/2) analyzed by western blotting. Data are representative of two
independent experiments.
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shown to be IL-17 positive and negative by ELISA as well as sections
of benign hyperplastic tonsil and benign dermatoses. In accordance
with the Declaration of Helsinki Principles (paragraph 25, October
2008) and Danish law, patient consent was not required as the
retrospective analyses of the archival tissue biopsies were performed
after specific approval and permission by the Danish Ethics
Committee (journal no. 01 284225) and the Institutional Review
Board. Only tissue sections not needed for diagnosis were used for
the analyses and the study was performed in accordance with the
Declaration of Helsinki Principles.
Cells
The malignant T-cell lines, SeAx and Sez-4, and the nonmalignant
T-cell line, MySi, were established from patients diagnosed with
CTCL (Kaltoft et al., 1987; Zhang et al., 2000; Woetmann et al.,
2007). The cell lines were cultured in RPMI-1640 supplemented
with 2mM L-glutamine, 100mgml–1 penicillin/streptomycin
(all from Sigma-Aldrich), 10% pooled human serum (Blood Bank,
State University Hospital, Copenhagen, Denmark), and 103Uml–1
IL-2. Before experimental use, the cells were starved for 24 hours in
media without IL-2. Peripheral blood mononuclear cells
were isolated from two patients diagnosed with SS and a healthy
donor as previously described (Kasprzycka et al., 2008). The
percentage of malignant T cells in the peripheral blood of the two
patients was 62% (P1) and 57% (P2) as judged from the number of
CD4þCD7–T cells. In experiments using small-molecule inhibitors,
the inhibitors were not washed out of the culture before addition of
cytokines.
ELISA
The concentrations of IL-17 in cell culture supernatants and human
serum were measured using the human IL-17 DuoSet ELISA
development kit from R&D Systems (Minneapolis, MN) in accor-
dance with the manufacture’s instructions. For analysis of IL-17 in
human serum, the standard curve samples were resuspended in
freshly prepared Reagent Diluent (1% BSA in phosphate-buffered
saline) and diluted 1:1 with human serum from healthy donors and
the serum samples were diluted 1:1 in Reagent Diluent.
RNA purification, reverse transcriptase-PCR, and quantitative
PCR
Total cellular mRNA was purified and reverse transcribed into
complementary DNA as described previously (Krejsgaard et al.,
2008). For reverse transcriptase-PCR, the complementary DNA was
amplified using recombinant Taq DNA polymerase (New England
Biolabs, Beverly, MA) with the following primers: glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)-forward: 50-CCATGGAGAAG
GCTGGGG-30, GAPDH-reverse: 50-CAAAGTTGTCATGGATGACC-
30, IL-17-forward: 50-TCATCCATCCCCAGTTGATT-30, IL-17-reverse:
50-GACCAGGATCTCTTGCTGGA-30. Quantitative PCR was per-
formed using the Brilliant II SYBR Green quantitative PCR kit from
Stratagene (La Jolla, CA) in accordance with the manufacturer’s
instructions and the samples analyzed on a Mx3000P (Stratagene).
For amplification of IL-17, the forward (0.1 mM) and reverse (0.3 mM)
primers noted above were used and for amplification of GAPDH the
following primers were used: 0.2 mM GAPDH-forward 50-AAGGTG
AAGGTCGGAGTCAA-30, 0.2 mM GAPDH-reverse 50-AATGAAGGG
GTCATTGATGG-30.
Transient transfections
Transient transfections were essentially performed as previously
described (Sommer et al., 2004) using 0.5 nmol Jak3, Stat3, Stat5,
or nontargeting (NT) ON-TARGETplus SMARTpool siRNA
(Dharmacon, Chicago, IL) and 2 106 cells.
Protein extraction and western blotting
Protein extraction and western blotting were performed as described
earlier (Krejsgaard et al., 2006). To ensure equal loading, the total
protein concentration of each lysate was determined by Bio-Rad
protein Assay (Bio-Rad, Hercules, CA).
Statistics
For statistical analysis, a two-tailed one-sample or two-sample
Student’s t-test with a significance level of 0.05 was used. The
asterisk symbol (*) denotes a significant difference (Po0.05)
between the indicated sample and the sample cultured without
inhibitor at the corresponding condition (with or without IL-2).
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